Skip to Main content Skip to Navigation
Journal articles

Multiple targeting by the antitumor drug tamoxifen: a structure-activity study.

Philippe de Médina 1 Gilles Favre 1 Marc E. Poirot 1 
1 Departement /u563 : Oncogenèse, Signalisation et Innovation thérapeutique
CPTP - Centre de Physiopathologie Toulouse Purpan, Institut Claudius Regaud
Abstract : Tamoxifen is a well-known antiestrogen used for the hormonotherapy of estrogen receptor positive breast cancer. In addition to its high affinity binding to the estrogen receptor (ER), tamoxifen binds with comparable affinity to the microsomal antiestrogen binding site (AEBS), and inhibits with a micromolar efficiency, protein kinase C (PKC), calmodulin (CaM)-dependent enzymes and Acyl CoenzymeA: Cholesterol Acyl Transferase (ACAT). Each of these tamoxifen targets might explain the genomic as well as non-genomic effects of tamoxifen. In this review, we will report current knowledge about the structural features of tamoxifen involved in this multiple targeting. These data provide a useful guide for the conception of selective ligands of ERs, AEBS, PKC, CaM or ACAT based on the chemical structure of tamoxifen.
Document type :
Journal articles
Complete list of metadata
Contributor : Marc Poirot Connect in order to contact the contributor
Submitted on : Saturday, September 2, 2006 - 11:42:38 PM
Last modification on : Wednesday, June 1, 2022 - 4:33:49 AM


  • HAL Id : inserm-00090772, version 1
  • PUBMED : 15579015



Philippe de Médina, Gilles Favre, Marc E. Poirot. Multiple targeting by the antitumor drug tamoxifen: a structure-activity study.. Current Medicinal Chemistry Anticancer Agents, Bentham Science Publishers, 2004, 4, pp.491-508. ⟨inserm-00090772⟩



Record views